Nektar Therapeutics Deferred Income Tax Expense (Benefit)
Nektar Therapeutics (NKTR) reported Deferred Income Tax Expense (Benefit) of $64.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-13
- Nektar Therapeutics deferred income tax expense (benefit) for the quarter ending 2024-12-31 was $2.00K, a 99.88% decline year-over-year.
- Nektar Therapeutics deferred income tax expense (benefit) for the quarter ending 2024-09-30 was -$31.00K.
- Nektar Therapeutics deferred income tax expense (benefit) for the quarter ending 2024-06-30 was $57.00K.
- Nektar Therapeutics deferred income tax expense (benefit) for the quarter ending 2024-03-31 was -$38.00K.
- Nektar Therapeutics deferred income tax expense (benefit) for fiscal 2025 was $64.00K.
- Nektar Therapeutics deferred income tax expense (benefit) for fiscal 2024 was -$10.00K.
- Nektar Therapeutics deferred income tax expense (benefit) for fiscal 2023 was -$140.00K, a 105.17% decline from fiscal 2022.
- Nektar Therapeutics deferred income tax expense (benefit) for fiscal 2022 was $2.71M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $64.00K 10-K · filed 2026-03-13 | |||
| 2024-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$29.00K derived: sum of 2 quarters · filed 2026-03-13 | $28.00K derived: sum of 3 quarters · filed 2026-03-13 | -$10.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $26.00K derived: sum of 2 quarters · filed 2024-11-08 | -$12.00K 10-Q · filed 2024-11-08 | $1.70M derived: sum of 4 quarters · filed 2025-03-14 |
| 2024-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $19.00K 10-Q · filed 2024-08-09 | $1.73M derived: sum of 3 quarters · filed 2025-03-14 | $1.72M derived: sum of 4 quarters · filed 2025-03-14 |
| 2024-03-31 | -$38.00K 10-Q · filed 2024-05-10 | $1.68M derived: sum of 2 quarters · filed 2025-03-14 | $1.66M derived: sum of 3 quarters · filed 2025-03-14 | $1.63M derived: sum of 4 quarters · filed 2025-03-14 |
| 2023-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $1.70M derived: sum of 2 quarters · filed 2025-03-14 | $1.67M derived: sum of 3 quarters · filed 2025-03-14 | -$140.00K 10-K · filed 2025-03-14 |
| 2023-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$42.00K derived: sum of 2 quarters · filed 2024-11-08 | -$1.85M 10-Q · filed 2024-11-08 | $854.00K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$1.84M 10-Q · filed 2024-08-09 | $869.00K derived: sum of 3 quarters · filed 2024-08-09 | $869.00K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$1.81M 10-Q · filed 2024-05-10 | $896.00K derived: sum of 2 quarters · filed 2024-05-10 | $896.00K derived: sum of 3 quarters · filed 2024-05-10 | $896.00K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $2.71M derived: sum of 2 quarters · filed 2024-03-05 | $2.71M derived: sum of 3 quarters · filed 2024-03-05 | $2.71M 10-K · filed 2024-03-05 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | -$102.00K 10-K · filed 2024-03-05 | |||
| 2020-12-31 | -$36.00K 10-K · filed 2023-02-28 | |||
| 2019-12-31 | -$21.00K 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $93.00K 10-K · filed 2021-02-26 | |||
| 2017-12-31 | $35.00K 10-K · filed 2020-02-28 | |||
| 2016-12-31 | -$115.00K 10-K · filed 2019-03-01 | |||
| 2015-12-31 | -$22.00K 10-K · filed 2018-03-01 | |||
| 2014-12-31 | -$31.00K 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $406.00K 10-K · filed 2016-02-29 | |||
| 2012-12-31 | -$487.00K 10-K · filed 2015-02-26 | |||
| 2011-12-31 | $96.00K 10-K · filed 2014-02-27 | |||
| 2010-12-31 | $180.00K 10-K · filed 2013-03-01 | |||
| 2009-12-31 | -$55.00K 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |